Journal of Neurogastroenterology and Motility

Table. 3. Table 3

Changes in Gastrointestinal Symptom Scores From Baseline at Week 4

GIS	Mosapride citrate SR group	Mosapride citrate CR group	Difference [95% CI]^a	P-value
PPS	n = 51	n = 49
Baseline	13.55 ± 5.21	13.84 ± 5.32		0.721^c
Week 4	3.51 ± 3.85	2.98 ± 3.11
Change^b	–10.04 ± 4.45	–10.86 ± 5.53	0.82 [–1.17, 2.81]	0.643^c
In group P-value	< 0.001^d	< 0.001^d
FAS	n = 57	n = 57
Baseline	13.55 ± 5.00	14.07 ± 5.58		0.541^c
Week 4	3.49 ± 3.82	3.70 ± 5.22
Change	–9.86 ± 4.48	–10.37 ± 6.23	0.51 [–1.51, 2.52]	0.820^c
In group P-value	< 0.001^d	< 0.001^d

GIS, gastrointestinal symptom scores; PPS, per-protocol set; FAS, full analysis set.

^aInter-group Difference [95% CI] = mosapride citrate SR-mosapride citrate CR 95% CI based on t test.

^bChanges in score related to symptoms (week 4-baseline).

^cWilcoxon rank sum test.

^dWilcoxon signed rank test.

J Neurogastroenterol Motil 2021;27:87~96 https://doi.org/10.5056/jnm20061